Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar 3;3(3):CD004610.
doi: 10.1002/14651858.CD004610.pub5.

Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults

Richard L Nelson  1 , Katie J Suda  2 , Charlesnika T Evans  3
Affiliations
Meta-Analysis

Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults

Richard L Nelson et al. Cochrane Database Syst Rev. .

Abstract

Background: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhoea and colitis. This review is an update of a previously published Cochrane review.

Objectives: The aim of this review is to investigate the efficacy and safety of antibiotic therapy for C. difficile-associated diarrhoea (CDAD), or C. difficile infection (CDI), being synonymous terms.

Search methods: We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017. We also searched clinicaltrials.gov and clinicaltrialsregister.eu for ongoing trials.

Selection criteria: Only randomised controlled trials assessing antibiotic treatment for CDI were included in the review.

Data collection and analysis: Three authors independently assessed abstracts and full text articles for inclusion and extracted data. The risk of bias was independently rated by two authors. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We pooled data using a fixed-effect model, except where significant heterogeneity was detected, at which time a random-effects model was used. The following outcomes were sought: sustained symptomatic cure (defined as initial symptomatic response and no recurrence of CDI), sustained bacteriologic cure, adverse reactions to the intervention, death and cost.

Main results: Twenty-two studies (3215 participants) were included. The majority of studies enrolled patients with mild to moderate CDI who could tolerate oral antibiotics. Sixteen of the included studies excluded patients with severe CDI and few patients with severe CDI were included in the other six studies. Twelve different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin, bacitracin, cadazolid, LFF517, surotomycin and fidaxomicin. Most of the studies were active comparator studies comparing vancomycin with other antibiotics. One small study compared vancomycin to placebo. There were no other studies that compared antibiotic treatment to a placebo or a 'no treatment' control group. The risk of bias was rated as high for 17 of 22 included studies. Vancomycin was found to be more effective than metronidazole for achieving symptomatic cure. Seventy-two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; moderate quality evidence). Fidaxomicin was found to be more effective than vancomycin for achieving symptomatic cure. Seventy-one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 95% CI 1.04 to 1.31; moderate quality evidence). Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure. Eightly-seven per cent (48/55) of teicoplanin patients achieved symptomatic cure compared to 73% (40/55) of vancomycin patients (RR 1.21, 95% CI 1.00 to 1.46; very low quality evidence). For other comparisons including the one placebo-controlled study the quality of evidence was low or very low due to imprecision and in many cases high risk of bias because of attrition and lack of blinding. One hundred and forty deaths were reported in the studies, all of which were attributed by study authors to the co-morbidities of the participants that lead to acquiring CDI. Although many other adverse events were reported during therapy, these were attributed to the participants' co-morbidities. The only adverse events directly attributed to study medication were rare nausea and transient elevation of liver enzymes. Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13 (Health Warehouse). Vancomycin 125 mg costs USD 1779 (Walgreens for 56 tablets) compared to fidaxomicin 200 mg at USD 3453.83 or more (Optimer Pharmaceuticals) and teicoplanin at approximately USD 83.67 (GBP 71.40, British National Formulary).

Authors' conclusions: No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic. Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other two antibiotics. The quality of evidence for teicoplanin is very low. Adequately powered studies are needed to determine if teicoplanin performs as well as the other antibiotics. A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin, would be of interest.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 Metronidazole vs Vancomycin, Outcome 1 Sustained Symptomatic Cure with all exclusions treated as failures.
1.2
1.2. Analysis
Comparison 1 Metronidazole vs Vancomycin, Outcome 2 Bacteriologic Cure.
1.3
1.3. Analysis
Comparison 1 Metronidazole vs Vancomycin, Outcome 3 Sustained Cure (Combined symptomatic and bacteriologic cure).
2.1
2.1. Analysis
Comparison 2 Bacitracin vs Vancomycin, Outcome 1 Symptomatic Cure.
3.1
3.1. Analysis
Comparison 3 Teicoplanin vs Vancomycin, Outcome 1 Symptomatic Cure.
3.2
3.2. Analysis
Comparison 3 Teicoplanin vs Vancomycin, Outcome 2 Bacteriologic Cure.
4.1
4.1. Analysis
Comparison 4 Metronidazole vs Fusidic Acid, Outcome 1 Symptomiatic Cure.
4.2
4.2. Analysis
Comparison 4 Metronidazole vs Fusidic Acid, Outcome 2 Bacteriologic Cure.
5.1
5.1. Analysis
Comparison 5 Fidaxomicin vs Vancomycin, Outcome 1 Symptomatic Cure.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anonymous 1994 {published data only}
    1. Anonymous. Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases 1994;26(3):309‐16. - PubMed
Boero 1990 {published data only}
    1. Boero M, Berti E, Morgando A, Verme G. Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica 1990;5(2):74‐7.
Cornley 2012 {published data only}
    1. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases 2012;12(4):281‐9. - PubMed
De Lalla 1992 {published data only}
    1. Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy 1992;36(10):2192‐6. - PMC - PubMed
Dudley 1986 {published data only}
    1. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine 1986;146(6):1101‐4. - PubMed
Fekety 1989 {published data only}
    1. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine 1989;86(1):15‐9. - PubMed
Garey 2011 {published data only}
    1. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 2011;66(12):2850‐5. - PubMed
Johnson 2014 {published data only}
    1. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan‐Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases 2014;59(3):345‐54. - PubMed
Keighley 1978 {published data only}
    1. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal 1978;2(6153):1667‐9. - PMC - PubMed
Lagrotteria 2006 {published data only}
    1. Lagrottereria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases 2006;43(5):547‐52. - PubMed
Lee 2016a {published data only}
    1. Lee CH, Patino H, Stevens C, Rege S, Chesnel L, Louie T, et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy 2016;71(10):2964‐71. - PubMed
Louie 2009 {published data only}
    1. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy 2009;53(1):223‐8. - PMC - PubMed
Louie 2011 {published data only}
    1. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine 2011;364(5):422‐31. - PubMed
Louie 2015 {published data only}
    1. Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy 2015;59(10):6266‐73. - PMC - PubMed
Mullane 2015 {published data only}
    1. Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy 2015;59(3):1435‐40. - PMC - PubMed
Musher 2006 {published data only}
    1. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases 2006;43(4):421‐7. - PubMed
Musher 2009 {published data only}
    1. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases 2009;48(4):41‐6. - PubMed
Teasley 1983 {published data only}
    1. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet 1983;2(8358):1043‐6. - PubMed
Wenisch 1996 {published data only}
    1. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases 1996;22(5):813‐8. - PubMed
Wullt 2004 {published data only}
    1. Wullt M, Odenholt I. A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy 2004;54(1):211‐6. - PubMed
Young 1985 {published data only}
    1. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA, et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89(5):1038‐45. - PubMed
Zar 2007 {published and unpublished data}
    1. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases 2007;45(3):302‐7. - PubMed

References to studies excluded from this review

Barker 2015 {published data only}
    1. Barker A, Duster M, Valentine S, Archbald‐Pannone L, Guerrant R, Safdar N. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double‐blind, randomized controlled trial. Contemporary Clinical Trials 2015;44:26‐32. - PMC - PubMed
Basu 2011 {published data only}
    1. Basu P, Krishnaswamy N, Shah J, Tang C. Comparison of nitazoxanide and vancomycin taper regimens as a salvage therapy for patients with recurrent mild to moderate Clostridium difficile infection (CDI). Gastroenteology 2011;140(5):s325.
Brumley 2016 {published data only}
    1. Brumley PE, Malani AN, Kabara JJ, Pisani J, Collins CD. Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 2016;71(3):836‐40. - PubMed
Cammarota 2015 {published data only}
    1. Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology and Therapeutics 2015;41(9):835‐43. - PubMed
De Bruyn 2016 {published data only}
    1. Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized phase 2 clinical trial. Vaccine 2016;34(19):2170‐8. - PubMed
Forster 2016 {published data only}
    1. Forster AJ, Daneman N, Walraven C. Influence of antibiotics and case exposure on hospital‐acquired Clostridium difficile infection independent of illness severity. Journal of Hospital Infection 2016 Oct 14 [Epub ahead of print]. [DOI: 10.1016/j.jhin.2016.10.007] - DOI - PubMed
Gerding 2016 {published data only}
    1. Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, et al. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. Journal of Antimicrobial Chemotherapy 2016;71(1):213‐9. - PMC - PubMed
Hossam 2016 {published data only}
    1. Hossam M, Elsisi G. Cost‐effectiveness analysis of fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in Egypt. Value in Health 2016;19(7):A513. - PubMed
Johnson 1992 {published data only}
    1. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine 1992;117(4):297‐302. - PubMed
Kaki 2016 {published data only}
    1. Kaki R, Brooks A, Main C, Jayaratne P, Mertz D. Does extending Clostridium difficile treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse?. Internet Journal of Infectious Diseases 2016;15(1):1‐5.
Lee 2016b {published data only}
    1. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 2016;315(2):142‐9. - PubMed
Lee 2016c {published data only}
    1. Lee C, Louie TJ, Weiss K, Valiquette L, Gerson M, Arnott W, et al. Fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology 2016;2016:Article Number: 8048757. - PMC - PubMed
Louie 2006 {published data only}
    1. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases 2006;43(4):411‐20. - PubMed
Lowy 2010 {published data only}
    1. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. New England Journal of Medicine 2010;362(3):197‐205. - PubMed
Mattila 2008 {published data only}
    1. Mattila E, Anttila VJ, Broas M, Marttila H, Poukka P, Kuusisto K, et al. A randomized, double‐blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile‐associated diarrhoea: Efficacy and safety of a prematurely interrupted trial. Scandinavian Journal of Infectious Diseases 2008;40(9):702‐8. - PubMed
McFarland 2002 {published data only}
    1. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. American Journal of Gastroenterology 2002;97(7):1769‐75. - PubMed
Mullane 2016 {published data only}
    1. Mullane KM, Adachi J, Dubberke E, Alexander B, Broyde N, Sears P. Outcomes of deflect‐1: A multicenter, blinded, randomized clinical trial of fidaxomicin (FDX) vs. placebo (PLC) for prophylaxis of Clostridium difficile‐associated diarrhea (CDAD) in subjects undergoing hematopoietic stem cell transplantation (HSCT). Biology of Blood and Marrow Transplantation 2016;22(3 Suppl 1):S171.
Noren 2006 {published data only}
    1. Noren T, Wullt M, Akerlund T, Back E, Odenholt I, Burman LG. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile‐associated diarrhea with fusidic acid. Antimicrobial Agents and Chemotherapy 2006;50(9):3028‐32. - PMC - PubMed
Numan 2007 {published data only}
    1. Numan SC, Veldkamp P, Kuijper EJ, Berg RJ, Dissel JT. Clostridium difficile‐associated diarrhoea: bovine anti‐clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007;56(6):888‐9. - PMC - PubMed
Thabit 2015 {published data only}
    1. Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. International Journal of Antimicrobial Agents 2015;46(2):205‐8. - PubMed
Welch 2016 {published data only}
    1. Welch HK, Nagel JL, Patel TS, Gandhi TN, Chen B, Leon J, et al. Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. American Journal of Infection Control 2016;44(12):1539‐43. - PMC - PubMed

References to studies awaiting assessment

Pardi 2012 {published data only (unpublished sought but not used)}
    1. Pardi DS, Brennan R, Spinnell M, Gareca MG, Greenberg E, Tian W, et al. The efficacy and safety of rifaximin vs. vancomycin in the treatment of mild to moderate C. difficile infection: A randomized double‐blind active comparator trial. Gastroenterology 2012;142(5 Suppl 1):S599.
Shyh 2014 {published data only (unpublished sought but not used)}
    1. Shyh G, Todorov D, Cohen H, Mukhtarzad R, Brooks S. Oral vancomycin plus intravenous metronidazole versus oral vancomycin in severe Clostridium difficile‐associated diarrhea: a single center study. Pharmacotherapy 2014;34(10):259‐60.

References to ongoing studies

NCT01983683 {unpublished data only}
    1. NCT01983683. A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01983683 (accessed 7 November 2013).
NCT01987895 {unpublished data only}
    1. NCT01987895. A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01987895 (accessed 7 November 2013).

Additional references

AHRQ 2016
    1. Minnesota Evidence‐based Practice Center. Early diagnosis, prevention and treatment of Clostridium difficile: Update. AHRQ Publication No. 16‐EHC012‐EF March, 2016; Vol. #172:1‐37.
Assmann 2000
    1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355(9209):1064‐9. - PubMed
Bagdasarian 2015
    1. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313(4):398‐408. - PMC - PubMed
Baker 2002
    1. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?. BMC Medical Research Methodology 2002;2:13. - PMC - PubMed
Bartlett 1980
    1. Bartlett JG, Taylor NS, Chang T, Dzink J. Clinical and laboratory observations in Clostridium difficile colitis. American Journal of Clinical Nutrition 1980;33(11 Suppl):2521‐6. - PubMed
Bartlett 1990
    1. Bartlett JG. Clostridium difficile: clinical considerations. Reviews of Infectious Diseases 1990;12 Suppl 2:S243‐51. - PubMed
Bartlett 2002
    1. Bartlett JG. Clinical practice. Antibiotic‐associated diarrhea. New England Journal of Medicine 2002;346(5):334‐9. - PubMed
Bauer 2009
    1. Bauer MP, Kuijper EJ, Dissel JT. European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection 2009;15(12):1067‐79. - PubMed
Bishara 2007
    1. Bishara J, Wattad M, Paul M. Vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases 2007;45(12):1646‐7. - PubMed
Bowden 1981
    1. Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. American Surgeon 1981;47(4):178‐83. - PubMed
Cohen 2010
    1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010;31(5):431‐55. - PubMed
Di 2015
    1. Di X, Bai N, Zhang X, Liu B, Ni W, Wang J, et al. A meta‐analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Brazilian Journal of Infectious Diseases 2015;19(4):339‐49. [PUBMED: 26001980] - PMC - PubMed
Drekonja 2011
    1. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Annals of Internal Medicine 2011;155(12):839‐47. - PubMed
Fekety 1993
    1. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269(1):71‐5. - PubMed
Fekety 1997
    1. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile‐associated diarrhea and colitis. American Journal of Gastroenterology 1997;92(5):739‐50. - PubMed
Garattini 2007
    1. Garattini S, Bertele V. Non‐inferiority trials are unethical because they disregard patients' interests. Lancet 2007;370:1875‐6. - PubMed
George 1982
    1. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent‐associated diarrhea and miscellaneous conditions. Journal of Clinical Microbiology 1982;15(6):1049‐53. - PMC - PubMed
Gerding 1995
    1. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile‐associated diarrhea and colitis. Infection Control and Hospital Epidemiology 1995;16(8):459‐77. - PubMed
Gotzsche 2006
    1. Gotzsche P. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006;295(10):1172‐4. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hopkins 2009
    1. Johns Hopkins. Teicoplanin. www.hopkins‐abxguide.org/antibiotics/antibacterial/glycopeptide/teicoplanin.html?con... 2009.
HPA 2008
    1. Health Protection Agency of the Department of Health, UK. Clostridium difficile infection: How to deal with the problem. www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851... (accessed 26 January 2017).
HPA 2016
    1. Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/dea... (accessed 26 January 2017).
Johnson 2012
    1. Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy 2012;56(8):4043‐5. - PMC - PubMed
Karas 2010
    1. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. Journal of Infection 2010;61(1):1‐8. - PubMed
Kelly 1994
    1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. New England Journal of Medicine 1994;330(4):257‐62. - PubMed
Khoruts 2010
    1. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile‐associated diarrhea. Journal of Clinical Gastroenterology 2010;44(5):354‐60. - PubMed
Laurence 2006
    1. Laurence J. Deaths from "dirty hospital bug" double in five years. The Independant 26 May, 2006:11.
Lessa 2015
    1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine 2015;372(9):825‐34. - PMC - PubMed
Locher 2014
    1. Locher HH, Caspers P, Bruyere T, Schroeder S, Pfaff P, Knezevic A, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrobial Agents and Chemotherapy 2014;58(2):901‐8. - PMC - PubMed
Louie 2005
    1. Louie TJ. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. Canadian Medical Association Journal 2005;173(9):1049‐50. - PMC - PubMed
McDonald 2005
    1. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene‐variant strain of Clostridium difficile. New England Journal of Medicine 2005;353(23):2433‐41. - PubMed
McFarland 1995
    1. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of beta‐lactam‐associated diarrhea by Saccharomyces boulardii compared with placebo. American Journal of Gastroenterology 1995;90(3):439‐48. - PubMed
Miesel 2014
    1. Miesel L, Hecht DW, Osmolski JR, Gerding D, Flattery A, Li F, et al. Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile. Antimicrobial Agents and Chemotherapy 2014;58(4):2387‐92. - PMC - PubMed
Novell 2010
    1. Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile‐associated diarrhea. Annals of Pharmacotherapy 2010;44(5):826‐31. - PubMed
Pepin 2005
    1. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile‐associated disease during an epidemic caused by a hypervirulent strain in Quebec. Canadian Medical Association Journal 2005;173(9):1037‐42. - PMC - PubMed
Privitera 1991
    1. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, Lalla F. Prosepctive study of Clostridium difficile intestinal colonization and disease following single‐dose antibiotic prophylaxis in surgery. Antimicrobial Agents and Chemotherapy 1991;35(1):208‐10. - PMC - PubMed
Redelings 2007
    1. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile‐related mortality rates, United States, 1999‐2004. Emerging Infectious Diseases 2007;13(9):1417‐9. - PMC - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, Available from www.cochrane‐handbook.org, 2011.
Sedgwick 2014
    1. Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. BMJ (Clinical research ed.) 2014;349:g6284. - PubMed
Soonawala 2010
    1. Soonawala D, Middelberg RA, Egger M, Vandenbroucke JP, Dekkers OM. Efficacy of experimental treatments compared with standard treatments in non‐inferiority trials: a meta‐analysis of randomized controlled trials.. International Journal of Epidemiology 2010;39(6):1567‐81. - PubMed
Sougioultzis 2005
    1. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile‐associated diarrhea. Gastroenterology 2005;128(3):764‐70. - PubMed
Steiner 2015
    1. Steiner C, Barrett M, Sun Y. HCUP projections: Clostridium difficile hospitalizations. HCUP Projections Report 2015;02:1‐12.
Stewart 2013
    1. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Disease 2013;15(7):798‐804. - PubMed
Thomas 2003
    1. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital‐acquired Clostridium difficile‐associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy 2003;51(6):1339‐50. - PubMed
Van Nood 2013
    1. Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal E, Vos W, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine 2013;368(5):407‐15. - PubMed
Vardakas 2012
    1. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents 2012;40(1):1‐8. - PubMed

References to other published versions of this review

Bricker 2005
    1. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004610.pub2] - DOI - PubMed
Nelson 2007
    1. Nelson R. Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004610.pub3] - DOI - PubMed
Nelson 2011
    1. Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, et al. Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD004610.pub4] - DOI - PubMed

MeSH terms